A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients

Table 4 Best overall tumor response

Tumor Response as per RECIST v1.1	Arm A, N = 3	Arm B, N = 5
Tumor Response as per RECIST v1.1	Number of patients	Number of patients
CR	0	0
PR	0	0
SD	1	2
PD	2	3

CR complete response, PR partial response, SD stable disease, PD progressive disease as per RECIST 1.1

ISSN: 1471-2407